25 June 2019

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name James Barder
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Amendment - additional disclosure to the Director Dealing announcement dated 19 November 2018 clarifying a voluntary surrender of options. All other details were and remain correct.
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument

Identification code
Ordinary Shares of 0.2 pence each

b) Nature of the transaction Surrender of options over ordinary shares
c) Price(s) and volume(s)

Price(s) Volume(s)
61.50 250,000
d) Aggregated information
-   Aggregated volume
-   Price
e) Date of the transaction 16th November 2018
f) Place of the transaction Outside a trading venue


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:

Bidhi Bhoma / Euan Brown / Kane Collings
Tel: +44 (0) 203 100 2000

For media enquiries please contact:

Optimum Strategic Communications
Mary Clark / Hollie Vile / Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144


Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com